LabGenomics랩지노믹스

LabGenomics is shrinking fast, with heavy operating losses, a share price down about 85% over a year, and no news coverage in the data.

LabGenomics, a Korean molecular diagnostics firm known for prenatal genetic tests, reported trailing revenue of about ₩77.6B against an operating loss of about ₩38.7B for the twelve months to H1 2026. Revenue has fallen from ₩202B in 2021 and the company has been loss-making since 2023, with the share price at ₩1,700 on 23 October 2026 near its 52-week low. Balance sheet figures show borrowings of ₩69.2B against cash of ₩9.3B.

What stands out

• Trailing operating margin is -49.8% and net margin is -66.5%, versus a 2021 operating margin of 51.6%.
• Free cash flow is negative at about -₩26.8B on a trailing basis, and cash of ₩9.3B is well below borrowings of ₩69.2B.
• The share price fell 41.9% over one month, 45.9% over three months and 85% over one year, with a 52-week high of ₩12,725.
• Price-to-book is 0.2 and price-to-sales is 0.3, but earnings-based multiples are not meaningful because the company is loss-making.
• Foreign ownership fell from 1.8% to 0% over sixty days, while the 20-day flows show foreign buying of about ₩344M and retail selling of about ₩432M.
• Recent filings include a share buyback decision on 23 October 2026, several trading halts in August and September, and an adjustment to the conversion price of the 5th series convertible bonds.

What to watch

• The buyback decision filed on 23 October 2026 and whether it is carried out.
• Any further trading halts, conversion price changes, or insider and major-holder filings, which have been frequent recently.
• The next periodic results, since the data does not include guidance or the reasons behind the 2025 loss increase, and no news headlines were available.